155 related articles for article (PubMed ID: 35428211)
1. Phase I study of [
Thivat E; Rouanet J; Auzeloux P; Sas N; Jouberton E; Levesque S; Billoux T; Mansard S; Molnar I; Chanchou M; Fois G; Maigne L; Chezal JM; Miot-Noirault E; D'Incan M; Durando X; Cachin F
BMC Cancer; 2022 Apr; 22(1):417. PubMed ID: 35428211
[TBL] [Abstract][Full Text] [Related]
2. Radiation dosimetry of [
Jouberton E; Perrot Y; Dirat B; Billoux T; Auzeloux P; Cachin F; Chezal JM; Filaire M; Labarre P; Miot-Noirault E; Millardet C; Valla C; Vidal A; Degoul F; Maigne L
Med Phys; 2018 Nov; 45(11):5251-5262. PubMed ID: 30179267
[TBL] [Abstract][Full Text] [Related]
3. [¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.
Viallard C; Perrot Y; Boudhraa Z; Jouberton E; Miot-Noirault E; Bonnet M; Besse S; Mishellany F; Cayre A; Maigne L; Rbah-Vidal L; D'Incan M; Cachin F; Chezal JM; Degoul F
Eur J Dermatol; 2015; 25(1):29-35. PubMed ID: 25548082
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Targeted Radionuclide Therapy Using [
Akil H; Quintana M; Raymond JH; Billoux T; Benboubker V; Besse S; Auzeloux P; Delmas V; Petit V; Larue L; D'Incan M; Degoul F; Rouanet J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804655
[TBL] [Abstract][Full Text] [Related]
5. Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent.
Bonnet-Duquennoy M; Papon J; Mishellany F; Labarre P; Guerquin-Kern JL; Wu TD; Gardette M; Maublant J; Penault-Llorca F; Miot-Noirault E; Cayre A; Madelmont JC; Chezal JM; Moins N
Int J Cancer; 2009 Aug; 125(3):708-16. PubMed ID: 19437532
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule.
Degoul F; Borel M; Jacquemot N; Besse S; Communal Y; Mishellany F; Papon J; Penault-Llorca F; Donnarieix D; Doly M; Maigne L; Miot-Noirault E; Cayre A; Cluzel J; Moins N; Chezal JM; Bonnet M
Int J Cancer; 2013 Sep; 133(5):1042-53. PubMed ID: 23404099
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
8. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52.
Mier W; Kratochwil C; Hassel JC; Giesel FL; Beijer B; Babich JW; Friebe M; Eisenhut M; Enk A; Haberkorn U
J Nucl Med; 2014 Jan; 55(1):9-14. PubMed ID: 24277756
[TBL] [Abstract][Full Text] [Related]
9. Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution.
Bonnet M; Mishellany F; Papon J; Cayre A; Penault-Llorca F; Madelmont JC; Miot-Noirault E; Chezal JM; Moins N
Pigment Cell Melanoma Res; 2010 Oct; 23(5):e1-11. PubMed ID: 20444199
[TBL] [Abstract][Full Text] [Related]
10. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
[TBL] [Abstract][Full Text] [Related]
11. Assessment of
Thivat E; Chanchou M; Mathieu S; Levesque S; Billoux T; Auzeloux P; Sas N; Molnar I; Jouberton E; Rouanet J; Fois G; Maigne L; Galmier MJ; Penault-Llorca F; Miot-Noirault E; Durando X; Cachin F
Front Med (Lausanne); 2022; 9():993151. PubMed ID: 36314021
[TBL] [Abstract][Full Text] [Related]
12. Targeted radiotherapy of pigmented melanoma with
Xu X; Yuan L; Gai Y; Liu Q; Yin L; Jiang Y; Wang Y; Zhang Y; Lan X
J Exp Clin Cancer Res; 2018 Dec; 37(1):306. PubMed ID: 30537980
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
Rbah-Vidal L; Vidal A; Billaud EM; Besse S; Ranchon-Cole I; Mishellany F; Perrot Y; Maigne L; Moins N; Guerquin-Kern JL; Degoul F; Chezal JM; Auzeloux P; Miot-Noirault E
Neoplasia; 2017 Jan; 19(1):17-27. PubMed ID: 27987437
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.
Viallard C; Chezal JM; Mishellany F; Ranchon-Cole I; Pereira B; Herbette A; Besse S; Boudhraa Z; Jacquemot N; Cayre A; Miot-Noirault E; Sun JS; Dutreix M; Degoul F
Oncotarget; 2016 Mar; 7(11):12927-36. PubMed ID: 26887045
[TBL] [Abstract][Full Text] [Related]
15. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
[TBL] [Abstract][Full Text] [Related]
16. Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.
Akil H; Rouanet J; Viallard C; Besse S; Auzeloux P; Chezal JM; Miot-Noirault E; Quintana M; Degoul F
Transl Oncol; 2019 Nov; 12(11):1442-1452. PubMed ID: 31421458
[TBL] [Abstract][Full Text] [Related]
17. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.
Giraudet AL; Cassier PA; Iwao-Fukukawa C; Garin G; Badel JN; Kryza D; Chabaud S; Gilles-Afchain L; Clapisson G; Desuzinges C; Sarrut D; Halty A; Italiano A; Mori M; Tsunoda T; Katagiri T; Nakamura Y; Alberti L; Cropet C; Baconnier S; Berge-Montamat S; Pérol D; Blay JY
BMC Cancer; 2018 Jun; 18(1):646. PubMed ID: 29884132
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
19. Phase I Trial of
D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
